The adoption of Ozempic in China: implications for public health and obesity control

In 2022, 38% of the population was overweight and 8% obese. China is experiencing a rapid rise in obesity. This phenomenon is worrying the health authorities and has prompted reaction from the public. Among the many fashionable weight-loss techniques and diets, there has been a boom in specialist drugs such as Ozempic (semaglutide).

GLP-1 and ozempic drugs

Ozempic, produced by Novo Nordisk under the name NovoCare in China, belongs to the GLP-1 class of drugs. Initially approved for type 2 diabetes, its field of action has recently been extended to the treatment of obesity. These drugs work by mimicking a hormone that regulates blood sugar levels and helps suppress appetite, making them useful for weight loss.

Regulatory and market advances

In 2024, the NMPA approved Ozempic for long-term weight management, a first for GLP-1 drugs in the country. This approval is seen as a response to rising obesity rates. At the same time, Eli Lilly’s tirzepatide has also been approved, signaling an opening of the market to these treatments. For the time being, the two companies together account for around 94% of total sales of GLP-1 drugs in China.

Questions and mixed opinions

Despite the popularity of Ozempic and other GLP-1 drugs, concerns remain about their side effects and high cost, which could limit their uptake. In addition, social networks reflect divided opinions, oscillating between enthusiasm for their efficacy and mistrust due to negative experiences.

Prospects for GLP-1 drugs on the Chinese market

Strong demand and public health concerns continue to stimulate interest in GLP-1 drugs. Players in the Chinese pharmaceutical sector have initiated their own research and development into GLP-1 drugs. Currently, Shanghai Benemae’s beinaglutide, the first GLP-1 drug developed in China, is undergoing clinical trials for the treatment of weight loss, with potential approval expected soon.  The companiesHengrui Medicine

Gan & Lee Pharmaceuticals and Haosen Pharmaceuticals are also investing heavily in research and development to bring GLP-1-based treatments to market.

Source: 36Kr, Designed by daxue consulting, GLP-1 anti-obesity drugs being researched in China

With patents about to expire and the emergence of potentially cheaper local products, the market could become more competitive and accessible. Transparency about the long-term effects and results will be crucial to winning consumer confidence.

For the full article and more details, see the Daxue dossier: Behind the burgeoning popularity of weight loss drug Ozempic in China

VVR Medical and Daxue Consulting specialise in providing strategic and operational support to companies in the medical sector on the Chinese market. Do not hesitate to contact us at contact@vvrmedical.com to receive advice and support from our experts for your project.